Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction

Nicholas L M Cruden, Catriona Graham, Scott A Harding, Christopher A Ludlam, Keith A A Fox, David E Newby

Research output: Contribution to journalArticlepeer-review

Abstract

Thrombolytic therapy fails to achieve reperfusion in almost a third of patients with acute myocardial infarction. Thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) are novel endogenous fibrinolytic and atherothrombotic factors that determine clot stability. We investigated whether admission plasma thrombin activatable fibrinolysis inhibitor (TAFI) and soluble CD40 ligand (sCD40L) concentrations predicted reperfusion following thrombolytic therapy in patients with acute myocardial infarction.
Original languageEnglish
Pages (from-to)189-97
Number of pages9
JournalThrombosis Research
Volume118
Issue number2
DOIs
Publication statusPublished - 2006

Fingerprint Dive into the research topics of 'Plasma TAFI and soluble CD40 ligand do not predict reperfusion following thrombolysis for acute myocardial infarction'. Together they form a unique fingerprint.

Cite this